Hybio Pharmaceutical Total Assets

Latest as of September 2025: CN¥3.17 Billion CNY ≈ $463.97 Million USD

Hybio Pharmaceutical total assets. Based on the latest financial reports, Hybio Pharmaceutical (300199) holds total assets worth CN¥3.17 Billion CNY (≈ $463.97 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Hybio Pharmaceutical worth for the company's overall valuation and market capitalisation.

Total Assets of Hybio Pharmaceutical (2007–2024)

Total assets of Hybio Pharmaceutical from 2007 to 2024. This chart illustrates how Hybio Pharmaceutical's total assets have evolved over time, based on quarterly financial data. See current stock price of Hybio Pharmaceutical for real-time trading data and today's change.

Hybio Pharmaceutical - Asset Composition Analysis

Hybio Pharmaceutical Total Assets Breakdown (December 2024)

Hybio Pharmaceutical total assets breakdown as of December 2024. Hybio Pharmaceutical's total assets of CN¥3.17 Billion consist of 15.4% current assets and 84.6% non-current assets.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	3.2%
Accounts Receivable	CN¥104.90 Million	3.5%
Inventory	CN¥238.63 Million	7.9%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥430.09 Million	14.3%
Goodwill	CN¥0.00	0.0%

Asset Composition Trend (2007–2024)

This chart illustrates how Hybio Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Hybio Pharmaceutical to assess how much short-term liquidity the company maintains relative to its equity base.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Hybio Pharmaceutical's current assets represent 15.4% of total assets in 2024, a decrease from 64.1% in 2007.
Cash Position: Cash and equivalents constituted 3.2% of total assets in 2024, up from 3.1% in 2007.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2007.
Asset Diversification: The largest asset category is intangible assets at 14.3% of total assets.

Hybio Pharmaceutical Competitors by Total Assets

Key competitors of Hybio Pharmaceutical based on total assets are shown below.

Company	Country	Total Assets
Jiangsu Nhwa Pharmaceutical Co Ltd SHE:002262	China	CN¥9.54 Billion
Tibet Rhodiola Pharmaceutical Holding Co SHG:600211	China	CN¥6.44 Billion
Shanghai Yizhong Pharmaceutical Co Ltd SHG:688091	China	CN¥1.54 Billion
Renhe Pharmacy Co Ltd SHE:000650	China	CN¥7.93 Billion
Bide Pharmatech Co. Ltd. A SHG:688073	China	CN¥2.54 Billion
Jianmin Pharmaceutical Group Co Ltd SHG:600976	China	CN¥4.69 Billion
Qianjiang Yongan Pharmaceutical Co Ltd SHE:002365	China	CN¥2.26 Billion
Shenzhen Neptunus Bioengineering Co Ltd SHE:000078	China	CN¥25.73 Billion

Hybio Pharmaceutical - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	0.37	0.43	0.95
Quick Ratio	0.18	0.23	0.78
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥-951.59 Million	CN¥-737.61 Million	CN¥-49.98 Million

Hybio Pharmaceutical - Advanced Valuation Insights

This section examines the relationship between Hybio Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	24.90
Latest Market Cap to Assets Ratio	0.91
Asset Growth Rate (YoY)	-8.2%
Total Assets	CN¥3.01 Billion
Market Capitalization	$2.74 Billion USD

Valuation Analysis

Near Book Valuation: The market values Hybio Pharmaceutical's assets close to their book value (0.91x), suggesting investors view the company's assets at approximately fair value.

Significant Asset Reduction: Hybio Pharmaceutical's assets decreased by 8.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Hybio Pharmaceutical (2007–2024)

The table below shows the annual total assets of Hybio Pharmaceutical from 2007 to 2024.

Year	Total Assets	Change
2024-12-31	CN¥3.01 Billion ≈ $440.20 Million	-8.21%
2023-12-31	CN¥3.28 Billion ≈ $479.56 Million	-9.25%
2022-12-31	CN¥3.61 Billion ≈ $528.44 Million	-7.56%
2021-12-31	CN¥3.91 Billion ≈ $571.63 Million	-2.83%
2020-12-31	CN¥4.02 Billion ≈ $588.30 Million	-14.91%
2019-12-31	CN¥4.72 Billion ≈ $691.38 Million	-16.53%
2018-12-31	CN¥5.66 Billion ≈ $828.28 Million	+6.84%
2017-12-31	CN¥5.30 Billion ≈ $775.27 Million	+18.87%
2016-12-31	CN¥4.46 Billion ≈ $652.20 Million	+25.69%
2015-12-31	CN¥3.55 Billion ≈ $518.89 Million	+108.90%
2014-12-31	CN¥1.70 Billion ≈ $248.39 Million	+31.72%
2013-12-31	CN¥1.29 Billion ≈ $188.58 Million	+14.71%
2012-12-31	CN¥1.12 Billion ≈ $164.40 Million	+8.48%
2011-12-31	CN¥1.04 Billion ≈ $151.55 Million	+386.48%
2010-12-31	CN¥212.89 Million ≈ $31.15 Million	+16.67%
2009-12-31	CN¥182.47 Million ≈ $26.70 Million	+33.63%
2008-12-31	CN¥136.55 Million ≈ $19.98 Million	+134.46%
2007-12-31	CN¥58.24 Million ≈ $8.52 Million	--

About Hybio Pharmaceutical

SHE:300199 China Drug Manufacturers - Specialty & Generic

Market Cap

$2.74 Billion

CN¥18.73 Billion CNY

Market Cap Rank

#4992 Global

#785 in China

Share Price

CN¥21.21

Change (1 day)

-3.98%

52-Week Range

CN¥16.36 - CN¥26.71

All Time High

CN¥29.95